<DOC>
<DOCNO>EP-0636367</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of phenylalkylamines for producing cholesterol lowering agents
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31138	A61P900	A61P306	C07C21100	A61K31138	C07C22508	A61K31135	C07C21722	C07C21718	A61P300	C07C22522	A61K31137	C07C21746	A61K31137	C07C22500	A61K31275	C07C21720	C07C21700	A61K31135	C07C21126	A61K3124	A61K31277	C07C25500	C07C25556	C07C22514	A61K3121	A61P910	C07C22516	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61P	A61P	C07C	A61K	C07C	A61K	C07C	C07C	A61P	C07C	A61K	C07C	A61K	C07C	A61K	C07C	C07C	A61K	C07C	A61K	A61K	C07C	C07C	C07C	A61K	A61P	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61P9	A61P3	C07C211	A61K31	C07C225	A61K31	C07C217	C07C217	A61P3	C07C225	A61K31	C07C217	A61K31	C07C225	A61K31	C07C217	C07C217	A61K31	C07C211	A61K31	A61K31	C07C255	C07C255	C07C225	A61K31	A61P9	C07C225	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Use of compounds of the formula 
<
IMAGE
>
  in which   one of R
<
1
>
 and R
<
2
>
 is C1-7-alkyl and the other is C1-7-alkyl or C2-6-alkenylmethyl, L is C1-11-alkylene or C2-11-alkenylene which is optionally bonded via an O atom to the phenyl group, or L is 1,4-phenylene,   n is 0 or, if L contains an O atom, n is 0 or 1,   Q is C1-7-alkyl, C2-10-alkenyl or a group of the formula Q': 
<
IMAGE
>
     R is H, halogen, CF3, CN or NO2,   R
<
3
>
 and R
<
4
>
 are H, C1-4-alkyl or halogen, and   R
<
5
>
 is H or, if R is H, H or halogen, and their pharmaceutically acceptable acid addition salts for producing cholesterol-lowering medicinal agents, and compounds covered by formula I.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
AEBI JOHANNES
</INVENTOR-NAME>
<INVENTOR-NAME>
GUERRY PHILIPE
</INVENTOR-NAME>
<INVENTOR-NAME>
JOLIDON SYNESE DR
</INVENTOR-NAME>
<INVENTOR-NAME>
MORAND OLIVIER
</INVENTOR-NAME>
<INVENTOR-NAME>
AEBI, JOHANNES
</INVENTOR-NAME>
<INVENTOR-NAME>
GUERRY, PHILIPE
</INVENTOR-NAME>
<INVENTOR-NAME>
JOLIDON, SYNESE, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
MORAND, OLIVIER
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of the compounds of the formula


wherein

one of R
1
 and R
2
is C
1-7
-alkyl and the other is C
1-7
-alkyl or C
2-6
-alkenyl-methyl,
L
is C
1-11
-alkylene or C
2-11
-alkenylene optionally bonded to the phenyl group via an O
atom or L is 1,4-phenylene,
n
= 0 or, where L contains an O atom, n = 0 or 1;
Q
is C
1-7
-alkyl, C
2-10
-alkenyl or a group of formula Q':

R
is H, halogen, CF
3
, CN or NO
2,
R
3
 and R
4
are H, C
1-4
-alkyl or halogen and
R
5
is H or, where R is H, H or halogen,

and their pharmaceutically acceptable acid addition salts for the manufacture of cholesterol-lowering
medicaments.
Use in accordance with claim 1, whereby n = 0 and R
5
 is H.
Use in accordance with claim 1 or 2, whereby

a) R
1
 is methyl and R
2
 is methyl, ethyl, propyl or allyl and/or
b) L is the group -CH=CHCH
2
O-, especially in the trans form, -(CH
2
)
5
 -, -(CH
2
)
6
-,
-(CH
2
) 
3
O-, -(CH
2
)
5
O-, -(CH
2
)
6
O- or 1,4-phenylene and/or
c) R
3
 is H, Br, Cl, F or CH
3
 and/or
d) Q is propyl, pentyl, isohexyl, 4-methyl-3-pentenyl or 2,6-dimethyl-5-heptenyl or 
e) Q is a group Q' in which R is H, Br, Cl, F, I, CF
3
, CN or NO
2
 and/or R
4
 is H, Br, Cl, F
or CH
3
, and/or R
5
 is H or F.
Use in accordance with claim 1 or 2, whereby


a) L is C
5-11
-alkylene or C
5-11
-alkyleneoxy, especially -(CH
2
)
6
- or -(CH
2
)
5
O-; C
3-11
-alkenyleneoxy,
especially -CH=CHCH
2
O-, or 1,4-phenylene and/or
b) R
3
 is H or halogen and/or
c) Q is C
2-10
-alkenyl, especially 4-methyl-3-pentenyl; or a group Q' in which R is CN,
NO
2
 or halogen, especially Br, Cl or F, and R
4
 is H or Cl.
Use in accordance with claim 4, whereby

a) R
1
 is methyl and R
2
 is methyl or allyl and/or
b) L is -(CH
2
)
5
O-, -CH=CHCH
2
O- or 1,4-phenylene and/or
c) R
3
 is H or F and/or
d) Q is 4-methyl-3-pentenyl or a group Q' in which R is Br, Cl, CN or NO
2
, R
4
 is H or Cl
and R
5
 is H.
Use in accordance with claim 1 or 2, whereby the compound is selected from
the following group:


trans-4-[[4-(Allylmethylamino)-2-butenyl]oxy]
-4'-bromobenzophenone,
trans-4-[[4-(allylmethylamino)-2-butenyl]oxy]
-4'-nitrobenzophenone,
p-[[4'-[(allylmethylamino)methyl]-4-biphenylyl]
carbonyl]benzonitrile,
2-chloro-4-nitrophenyl 4'-[(dimethylamino)methyl]-4-biphenylyl ketone,
trans-4-[[4-(allylmethylamino)-2-butenyl]oxy]
 -2',4'-dichlorobenzophenone.
Use in accordance with claim 1, whereby the compound is selected from the
following group:


[4-[6-(Allyl-methyl-amino)-hexyloxy]-phenyl]
-(4-bromo-phenyl)-methanone,
[4-[6-(allyl-methyl-amino)-hexyloxy]-3-fluoro-phenyl]
-(4-bromo-phenyl)-methanone, 
[4-[6-(allyl-methyl-amino)-hexyloxy] -2-fluoro-phenyl]
-(4-bromo-phenyl)-methanone,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-3-fluoro-phenyl]
-(4-bromo-phenyl)-methanone,
(E)-1-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-phenyl]
-5-methyl-hex-4-en-1-one,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-2-fluoro-phenyl]
 -(4-bromo-phenyl)-methanone.
The compounds of formula I in accordance with claim 1 or 2 selected from the
following group:


4-[[6-(Allylmethylamino)hexyl]oxy]
-3-chlorobenzophenone,
4-[[6-(allylmethylamino)hexyl]oxy]
-3,4'-dibromobenzophenone,
4-[[4-(allylmethylamino)-2-butenyl]oxy]
-3,4'-dibromobenzophenone,
3-chloro-4'-iodo-4-[[6-(allylmethylamino)hexyl]oxy]
benzophenone,
4'-bromo-3-chloro-4-[[6-(allylmethylamino)hexyl]oxy]
benzophenone,
2,4-[[(4-dimethylamino)-2-butenyl]oxy]
-3,4'-dibromobenzophenone,
4-[[4-(dimethylamino)-2-butenyl]oxy]
-3-chlorobenzophenone,
4'-bromo-3-chloro-4-[[6-(dimethylamino)hexyl]oxy]
benzophenone,
3,4-dichlorophenyl 4'-[(dimethylamino)methyl]-4-biphenylyl ketone,
4'-[(allylmethylamino)methyl]-4-biphenylyl 3,4-dichlorophenyl ketone,
(RS)-4'-(dimethylaminomethyl)-4-biphenyl 2,6-dimethyl-5-heptenyl ketone,
p-bromphenyl 2-chloro-4'-[(dimethylamino)methyl]-4-biphenylyl ketone,
4'-[(dimethylamino)methyl]-4-biphenylyl propyl ketone.
The compounds of formula I in accordance with claim 1 selected from the
following group:


[4-[6-(Allyl-methyl-amino)-hexyloxy]-phenyl]
 -(4-bromo-phenyl)-methanone,
[4-[4-(allyl-methyl-amino)-butoxy]-phenyl]
-(4-bromo-phenyl)-methanone,
[4-[6-(allyl-methyl-amino)-hexyloxy]-3-fluoro-phenyl]
-(4-bromo-phenyl)-methanone,
[4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl]
-(4-bromo-phenyl)-methanone,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-phenyl]
-(4-trifluoromethyl-phenyl)-methanone,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-3-fluoro-phenyl]
-(4-bromo-phenyl)-methanone,
(E)-1-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-phenyl]
-5-methyl-hexan-1-one, 
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-phenyl]
-(4-iodo-phenyl)-methanone,
(E)-1-[4-(allyl-methyl-amino)-but-2-enyloxy]-3-fluoro-phenyl]
-5-methyl-hexan-1-one,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-3-fluoro-benzoyl]
-benzonitrile,
(E)-4-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-benzoyl]
-benzonitrile,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-3-fluoro-phenyl]
-(2,6-difluoro-phenyl)-methanone,
(E)-1-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-phenyl]
-5-methyl-hex-4-en-1-one,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-2-fluoro-phenyl]
-(4-bromo-phenyl)-methanone,
(E)-[4-[4-(allyl-methyl-amino)-but-2-enyloxyl-phenyl]-(4-fluoro-phenyl)-methanone,
(E)-1-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-3-fluoro-phenyl]
-6-methyl-hept-5-en-2-one,
(E)-2-[4-[4-(allyl-methyl-amino)-but-2-enyloxy]-3-fluoro-phenyl]
-1-(4-bromo-phenyl)-ethanone,
(E)-2-[4-[4-(allyl-methyl-amino)-but-2-enyloxy)-phenyl]-1-(4-bromo-phenyl)-ethanone,
(E)-(4-bromo-phenyl)-[4-[4-(ethyl-methyl-amino)-but-2-enyloxy]-phenyl]
-methanone,
4'-[(allylmethylamino)methyl]-2-chloro-4-biphenyly p-bromophenyl ketone.
</CLAIMS>
</TEXT>
</DOC>
